{"id":"https://openalex.org/W2248901366","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.2559","title":"Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors","display_name":"Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors","publication_year":2009,"publication_date":"2009-05-20","ids":{"openalex":"https://openalex.org/W2248901366","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.2559","mag":"2248901366"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2009.27.15_suppl.2559","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.2559","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2009.27.15_suppl.2559","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5019052781","display_name":"Colin R. Lindsay","orcid":"https://orcid.org/0000-0001-8167-5461","observed_orcids":["https://orcid.org/0000-0001-8167-5461"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I4210143228","display_name":"Cancer Research UK Scotland Institute","ror":"https://ror.org/03pv69j64","country_code":"GB","type":"facility","lineage":["https://openalex.org/I2801316944","https://openalex.org/I4210143228"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"C. R. Lindsay","raw_affiliation_strings":["Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I4210143228","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112027022","display_name":"Emily Chan","orcid":"https://orcid.org/0009-0007-2231-8123","observed_orcids":["https://orcid.org/0009-0007-2231-8123"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I4210143228","display_name":"Cancer Research UK Scotland Institute","ror":"https://ror.org/03pv69j64","country_code":"GB","type":"facility","lineage":["https://openalex.org/I2801316944","https://openalex.org/I4210143228"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"E. Chan","raw_affiliation_strings":["Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I4210143228","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014220064","display_name":"Thomas R. Jeffry Evans","orcid":"https://orcid.org/0000-0001-5201-885X","observed_orcids":["https://orcid.org/0000-0001-5201-885X"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I4210143228","display_name":"Cancer Research UK Scotland Institute","ror":"https://ror.org/03pv69j64","country_code":"GB","type":"facility","lineage":["https://openalex.org/I2801316944","https://openalex.org/I4210143228"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"T. R. Evans","raw_affiliation_strings":["Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I4210143228","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053848443","display_name":"Sophia Campbell","orcid":"https://orcid.org/0009-0005-9769-7936","observed_orcids":["https://orcid.org/0009-0005-9769-7936"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I4210143228","display_name":"Cancer Research UK Scotland Institute","ror":"https://ror.org/03pv69j64","country_code":"GB","type":"facility","lineage":["https://openalex.org/I2801316944","https://openalex.org/I4210143228"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"S. Campbell","raw_affiliation_strings":["Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I4210143228","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":null,"display_name":"P. Bell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I4210143228","display_name":"Cancer Research UK Scotland Institute","ror":"https://ror.org/03pv69j64","country_code":"GB","type":"facility","lineage":["https://openalex.org/I2801316944","https://openalex.org/I4210143228"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"P. Bell","raw_affiliation_strings":["Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I4210143228","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021075936","display_name":"Andrew Wills Stephens","orcid":"https://orcid.org/0000-0001-5052-6586","observed_orcids":["https://orcid.org/0000-0001-5052-6586","https://orcid.org/0000-0002-4434-2307"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I4210143228","display_name":"Cancer Research UK Scotland Institute","ror":"https://ror.org/03pv69j64","country_code":"GB","type":"facility","lineage":["https://openalex.org/I2801316944","https://openalex.org/I4210143228"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"A. W. Stephens","raw_affiliation_strings":["Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I4210143228","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018071188","display_name":"Amy Franke","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I4210143228","display_name":"Cancer Research UK Scotland Institute","ror":"https://ror.org/03pv69j64","country_code":"GB","type":"facility","lineage":["https://openalex.org/I2801316944","https://openalex.org/I4210143228"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"A. Franke","raw_affiliation_strings":["Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I4210143228","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103019090","display_name":"Srinivasu Poondru","orcid":"https://orcid.org/0009-0002-8807-9894","observed_orcids":["https://orcid.org/0009-0002-8807-9894"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I4210143228","display_name":"Cancer Research UK Scotland Institute","ror":"https://ror.org/03pv69j64","country_code":"GB","type":"facility","lineage":["https://openalex.org/I2801316944","https://openalex.org/I4210143228"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"S. Poondru","raw_affiliation_strings":["Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I4210143228","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109982877","display_name":"Mace L. Rothenberg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I4210143228","display_name":"Cancer Research UK Scotland Institute","ror":"https://ror.org/03pv69j64","country_code":"GB","type":"facility","lineage":["https://openalex.org/I2801316944","https://openalex.org/I4210143228"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"M. L. Rothenberg","raw_affiliation_strings":["Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I4210143228","https://openalex.org/I4390039299"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5049243227","display_name":"Igor J. Puzanov","orcid":"https://orcid.org/0000-0002-9803-3497","observed_orcids":["https://orcid.org/0000-0002-9803-3497"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I4210143228","display_name":"Cancer Research UK Scotland Institute","ror":"https://ror.org/03pv69j64","country_code":"GB","type":"facility","lineage":["https://openalex.org/I2801316944","https://openalex.org/I4210143228"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"I. Puzanov","raw_affiliation_strings":["Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beatson Institute for Cancer Research, Glasgow, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; OSI Pharmaceuticals (UK) Ltd, Oxford, United Kingdom; OSI Pharmaceuticals, Inc, Boulder, CO","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I4210143228","https://openalex.org/I4390039299"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":20,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"27","issue":"15_suppl","first_page":"2559","last_page":"2559"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10748","display_name":"Growth Hormone and Insulin-like Growth Factors","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10748","display_name":"Growth Hormone and Insulin-like Growth Factors","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/osi-906","display_name":"OSI-906","score":0.9990000128746033},{"id":"https://openalex.org/keywords/igf-1-receptor","display_name":"IGF-1 receptor","score":0.8299999833106995},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8920000195503235},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7429999709129333},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8830000162124634},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8949999809265137},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.902999997138977},{"id":"https://openalex.org/keywords/hyperglycemia","display_name":"hyperglycemia","score":0.8799999952316284},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5490000247955322},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7429999709129333},{"id":"https://openalex.org/keywords/thymic-carcinoma","display_name":"thymic carcinoma","score":0.6320000290870667},{"id":"https://openalex.org/keywords/adrenocortical-carcinoma","display_name":"adrenocortical carcinoma","score":0.9110000133514404},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.9909999966621399}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8604439496994019},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.616698682308197},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.605991005897522},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5753499269485474},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5473952889442444},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5124795436859131},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5122701525688171},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.5025954246520996},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4733959436416626},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.46623867750167847},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.43796834349632263},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.43518149852752686},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3594205975532532}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2009.27.15_suppl.2559","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.2559","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2009.27.15_suppl.2559","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2589293705","https://openalex.org/W2244796562","https://openalex.org/W2163205418","https://openalex.org/W2964703132","https://openalex.org/W2140498074","https://openalex.org/W4230962117","https://openalex.org/W2089069627","https://openalex.org/W2264871646","https://openalex.org/W2563667280","https://openalex.org/W2242384250"],"abstract_inverted_index":{"2559":[0],"Background:":[1],"OSI-906":[2,119,160,189,231],"is":[3,22,256,276],"a":[4,11],"potent":[5],"small":[6],"molecule":[7],"inhibitor":[8],"of":[9,42,51,101,157,230],"IGF-1R,":[10],"receptor":[12],"tyrosine":[13],"kinase":[14],"activated":[15],"by":[16],"insulin":[17,186],"like":[18],"growth":[19],"factor,":[20],"which":[21],"overexpressed":[23],"in":[24,29,60,152,199,233,242,277],"numerous":[25],"malignancies":[26],"and":[27,64,86,90,95,122,134,175,188,215,248,272],"implicated":[28],"resistance":[30],"to":[31,118,129,258,266],"chemotherapy.":[32],"Methods:":[33],"Patients":[34],"with":[35,209],"advanced":[36],"cancer":[37],"entered":[38],"escalating":[39],"dose":[40,274],"cohorts":[41],"OSI-906.":[43],"Study":[44],"objectives":[45],"included":[46],"assessment":[47],"of:":[48],"safety;":[49],"determination":[50],"MTD;":[52],"pharmacokinetics":[53],"(PK),":[54],"pharmacodynamics":[55],"(PD)":[56],"including":[57,205],"IGF-1R":[58,222],"levels":[59,187],"peripheral":[61],"blood":[62],"cells;":[63],"tumor":[65],"response":[66],"(RECIST).":[67],"Results:":[68],"To":[69],"date,":[70],"32":[71],"pts":[72,201],"have":[73,111,252],"been":[74,112,253],"treated":[75],"(22M/10F,":[76],"median":[77,164],"age":[78],"62y)":[79],"at":[80,91],"10,":[81],"20,":[82,92],"40,":[83],"75,":[84],"150,":[85],"300":[87],"mg":[88,94,97],"QD":[89],"40":[93],"75":[96],"BID.":[98],"Median":[99],"number":[100],"weeks":[102,196],"on":[103,221],"trial":[104,235],"was":[105,120,147,180,197,270],"6":[106],"(range":[107,202],"0\u201344).":[108],"No":[109],"DLTs":[110],"observed.":[113,254],"Hyperglycemia":[114],"(5/20":[115,136],"pts)":[116,137],"related":[117,142],"transient":[121],"mild":[123],"(grade":[124],"1":[125,153,206],"only).":[126],"In":[127],"addition":[128],"hyperglycemia,":[130],"grade":[131,148],"1\u20132":[132],"nausea":[133],"vomiting":[135],"were":[138],"the":[139],"most":[140],"frequent":[141],"adverse":[143],"events":[144],"(AEs).":[145],"There":[146,179],"3":[149],"elevated":[150],"lipase":[151],"pt.":[154],"At":[155],"doses":[156],"10\u2013150":[158],"mg,":[159],"exhibited":[161],"linear":[162],"PK,":[163],"terminal":[165],"t1/2":[166],"ranged":[167],"from":[168,172],"2.18\u20134.30":[169],"hr,":[170],"AUC0-inf":[171],"284\u201310200":[173],"ng.hr/mL,":[174],"Cmax":[176],"76.6\u20131440":[177],"ng/mL.":[178],"no":[181],"relationship":[182],"between":[183],"glucose":[184],"or":[185],"plasma":[190],"concentrations.":[191],"Stable":[192],"disease":[193],">":[194],"12":[195],"seen":[198],"7/20":[200],"12\u201334":[203],"weeks),":[204],"pt":[207],"each":[208],"thymic":[210],"(27":[211],"w),":[212],"adrenocortical":[213],"(28w),":[214],"colorectal":[216],"(34w)":[217],"cancer.":[218],"PD":[219,245],"data":[220],"phosphorylation":[223],"will":[224],"be":[225],"presented.":[226],"Conclusions:":[227],"Plasma":[228],"concentrations":[229,237],"achieved":[232],"this":[234],"exceed":[236],"required":[238],"for":[239],"antitumor":[240],"efficacy":[241],"preclinical":[243],"models.":[244],"target":[246],"modulation":[247],"preliminary":[249],"anti-tumor":[250],"activity":[251],"It":[255],"interesting":[257],"note":[259],"that":[260],"clinically":[261],"meaningful":[262],"hyperglycemia":[263],"has":[264],"yet":[265],"occur.":[267],"Minimal":[268],"toxicity":[269],"observed":[271],"further":[273],"escalation":[275],"progress.":[278],"[Table:":[279],"see":[280],"text]":[281]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2016-06-24T00:00:00"}